Helen DeVos Children’s Hospital Chooses TransMed Systems to Support Molecular Oncology Programs
Helen DeVos Children’s Hospital has chosen TransMed Systems to support its advanced translational medicine programs in pediatric oncology.
Grand Rapids, MI (PRWEB) April 03, 2014
Helen DeVos Children’s Hospital has chosen TransMed Systems to support its advanced translational medicine programs in pediatric oncology. Helen De Vos Children’s Hospital, a part of the Spectrum system, is a member of the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC). The NMTRC is comprised of 15 pediatric hospitals across the US.
TransMed provides a unique software solution designed to support translational research and personalized medicine. It has been built from the ground up and engineered to address some of the toughest challenges in healthcare information technology.
Unique patent pending connectivity capabilities enabling customers to integrate their many electronic data capture systems such as their EMR and lab systems in to a single repository for exploration, discovery and reporting.
- Ability to connect clinical data with molecular data such as gene expression and mutation data from any commercially available systems creating a longitudinal patient record with all clinical and molecular data available for clinical decision making.